iGATE Corporation (NASDAQ:IGTE) reported Q3 financial results on Wednesday, with earnings in-line with the consensus of analysts polled by Capital IQ and revenues slightly beating the consensus. iGATE Corporation (NASDAQ:IGTE), the Pittsburgh-based technology consulting and outsourcing firm reported Q3 net income attributable to the company of $37.3 million, or $0.52 per diluted share, compared to $31.9 million, or $0.46 per diluted share in the year-ago period. Analysts were expecting EPS of $0.52 per share. Revenues rose 10% year-on-year to $322.8 million, slightly beating the consensus of $322.02 million. Gross margins fell to 35.3% from 41.4% in Q3 2013.IGTE President and CEO Ashok Vemuri said, ""I am pleased that we are able to sustain our broad-based growth both sequentially as well as year over year," adding, "We are pleased to be the only IT services company to be listed in Fortune 100 Fastest-Growing Companies in the U.S., further validating our go-to-market strategy." IGTE closed higher at $34.74 on Tuesday, in a 52-week range of $28.58-$42.90.Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company focused on the treatment of obesity, said Wednesday it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related to the shipment of its Contrave weight-management treatment (naltrexone HCI and bupropion HCI extended release) to pharmacy wholesalers in preparation for commercial launch. The latest milestone payment, payable within 30 days of invoice, comes after Orexigen on Oct. 7 received from Takeda $30 million in milestone payments that were earned in September with the approval of Contrave by the U.S. Food and Drug Administration and the delivery to Takeda of Contrave launch supplies. Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Orexigen Therapeutics, Inc. (NASDAQ:OREX) said it now expects to end 2014 with approximately $190 million in cash, cash equivalents and marketable securities.Alcoa Inc (NYSE:AA) said it has agreed to sell its ownership stake in the Jamalco bauxite mining and alumina refining joint venture to Noble for $140 million. Alcoa Inc (NYSE:AA) is trading within a 52-week range of $8.35 - $17.36. The sale is seen closing by the end of Q4 and Alcoa said it expects to record a non-cash loss of approximately $80 million to $100 million, or between $0.07 and $0.09 per share, after-tax and non-controlling interest in Q4, as a result of the transaction. The aluminum producer and maker of lightweight metals products said the Alcoa World Alumina and Chemicals unit will continue to manage operations of the JV for three years under a compensated service agreement and employees will remain employed by Jamalco.The joint venture is 55% owned by Alcoa Minerals of Jamaica (AMJ) and 45% owned by Clarendon Alumina Production Ltd. AMJ is part of the AWAC joint venture, owned 60% by Alcoa and 40% by Alumina Limited. CAP is a company wholly owned by the Government of Jamaica. "The decision to sell AWAC's stake in Jamalco is in line with Alcoa's global strategy to reshape its upstream portfolio and lower the cost base of our commodity business, Bob Wilt, president of Alcoa Global Primary Products, said in a statement.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
